Semaglutide treatment linked to over 4-fold increased risk of NAION in diabetic patients

Type 2 Diabetes (T2D) management requires careful consideration of both glycemic control and long-term safety. While GLP-1 receptor agonists (GLP-1RAs) like semaglutide offer significant benefits, understanding their full risk profile, including rare but serious adverse events, is crucial for patient care. Non-arteritic anterior ischemic optic neuropathy (NAION) is a sudden vision loss condition that warrants investigation in the context of new therapies.

Hathaway et al. conducted a single-center observational study comparing diabetic patients treated with semaglutide to those receiving other antidiabetic medications. The study aimed to identify potential associations between semaglutide use and the incidence of non-arteritic anterior ischemic optic neuropathy (NAION). Patient data was analyzed to determine the relative risk of NAION in the semaglutide group, using a hazard ratio (HR) as the primary endpoint.

Diabetic patients treated with semaglutide exhibited a significantly increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). > This risk was quantified by a hazard ratio (HR) of 4.28 when compared to diabetic patients receiving a different antidiabetic medication. This finding suggests a substantial elevation in the likelihood of developing this vision-threatening condition among semaglutide users, specifically within a diabetic population.